Noble Financial analyst Ahu Demir maintained a Buy rating on TrovaGene (TROV) on January 15. The company’s shares closed yesterday at $0.53, close to its 52-week low of $0.50.
According to TipRanks.com, Demir is ranked #3255 out of 5151 analysts.
Currently, the analyst consensus on TrovaGene is a Moderate Buy with an average price target of $3.
See today’s analyst top recommended stocks >>
Based on TrovaGene’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.77 million. In comparison, last year the company had a GAAP net loss of $2.57 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor.
